ARVs as HIV prevention: A tough road to wide impact

Science

Volumn 334, Issue 6063, 2011, Pages 1645-1646

  Shelton, James D ^a  

^a Bureau for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; DISEASE CONTROL; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS;

COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LONG TERM CARE; MALE HOMOSEXUAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; ANTIVIRAL RESISTANCE; ARTICLE; COST; DISEASE TRANSMISSION; DRUG EFFECT; ECONOMICS; EPIDEMIC; FEMALE; HIGH RISK BEHAVIOR; HUMAN IMMUNODEFICIENCY VIRUS; MALE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SERODIAGNOSIS; VIROLOGY;

DISTRICT OF COLUMBIA; UNITED STATES; WASHINGTON [DISTRICT OF COLUMBIA];

ADMINISTRATION, ORAL; AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; COSTS AND COST ANALYSIS; DRUG RESISTANCE, VIRAL; EPIDEMICS; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; RISK-TAKING; SEXUAL BEHAVIOR;

EID: 84455163426     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1212353     Document Type: Review

References (33)

1. M. S. Cohen et al., N. Engl. J. Med. 365, 493 (2011).
2. J. Cohen, Science 333, 393 (2011).
3. UNAIDS, AIDS at 30: Nations at the Crossroads (UNAIDS, Geneva, 2011); www.unaids.org/unaids-resources/aidsat30/aids-at-30.pdf.
4. J. Cohen, ScienceInsider 28 September 2011; http://news.sciencemag.org/ scienceinsider/2011/09/a-dizzying-second-twist-in-trial.html.
5. UNAIDS, World AIDS Day Report (UNAIDS, Geneva, 2011); www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/ JC2216-WorldAIDSday-report-2011-en.pdf.
6. Lesotho Ministry of Health and Social Welfare, Lesotho Demographic and Health Survey 2009 (Ministry of Health and Social Welfare, Maseru, Lesotho, and ICF Macro, Calverton, MD, 2010); www.measuredhs.com/pubs/pdf/FR241/FR241.pdf.
7. R. M. Granich et al., Lancet 373, 48 (2009).
8. M. S. Cohen et al., N. Engl. J. Med. 364, 1943 (2011).
9. S. M. Goodreau et al., AIDS Behav. 30 December 2010, 10.1007/s10461-010- 9858-x.
10. R. P. Dalal et al., J. Acquir. Immune Defic. Syndr. 47, 101 (2008).
11. K. B. Patterson et al., Sci. Transl. Med. 3, 112re4 (2011).
12. R. L. Hamers et al., Lancet Infect. Dis. 11, 750 (2011).
13. C. B. Hurt, J. J. Evon Jr., M. S. Cohen, Clin. Infect. Dis. 53, 1265 (2011).
14. P. Kajubi et al., J. Acquir. Immune Defic. Syndr. 40, 77 (2005).
15. I. A. V. Jansen et al., AIDS 25, 493 (2011).
16. B. Hasse et al., Clin. Infect. Dis. 51, 1314 (2010).
17. B. Fernandez-Fernandez et al., Aids Res. Treat. 2011, 1 (2011).
18. B. A. I. Payne et al., Nat. Genet. 43, 806 (2011).
19. B. Schwartländer et al., Lancet 377, 2031 (2011).
20. G. A. Millett et al., J. Acquir. Immune Defic. Syndr. 55, (suppl. 2), S144 (2010).
21. B. G. Brenner et al., AIDS 22, 2509 (2008).
22. R. M. Grant et al., N. Engl. J. Med. 363, 2587 (2010).
23. E. M. Gardner et al., Clin. Infect. Dis. 52, 793 (2011).
24. R. Trubo, JAMA 306, 253 (2011).
25. M. Das et al., PLoS ONE 5, e11068 (2010).
26. J. S. Montaner et al., Lancet 376, 532 (2010).
27. J. D. Shelton et al., Lancet 376, 1824 (2010).
28. A. E. Grulich, D. P. Wilson, Lancet 376, 1824 (2010).
29. J. Prejean et al., PLoS ONE 6, e17502 (2011).
30. D. Donnell et al., Lancet 375, 2092 (2010).
31. PEPFAR, 2011, www.pepfar.gov/documents/organization/177126.pdf.
32. R. Granich et al., Curr. HIV Res. 9, 446 (2011).
33. D. T. Halperin et al., PLoS Med. 8, e1000414 (2011).